Clinical Trials Flood India But Infrastructure Woes Stifle Cancer Trials
This article was originally published in PharmAsia News
Executive Summary
AHMEDABAD, India - As the number of clinical trials grow steadily in India to reach over $1 billion in turnover, a peculiar "problem of plenty" faces clinical trials for specialized cancer drugs
You may also be interested in...
Sneak Preview: R&D Investments Must Focus On India’s Competitive Advantages
India has unique capabilities for genomic databases, translational research and nanotechnology, which should spur research on cancer leads, according to a BCG report to be released May 11.
Sneak Preview: R&D Investments Must Focus On India’s Competitive Advantages
India has unique capabilities for genomic databases, translational research and nanotechnology, which should spur research on cancer leads, according to a BCG report to be released May 11.
Patient Safety First: Indian Regulator Takes Steps To Tighten Grip Over Site Inspections, Ensure Data Credibility
MUMBAI - As India moves rapidly to become an integral part of large-scale global clinical trials, the Central Drugs Standard Control Organization under the Ministry of Health and Family Welfare has declared a set of new guidelines to ensure adequate safety of trial participants